CTIS2024-513977-31-00进行中（未招募）1 期
A phase II trial of radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck (REWRITe) - GORTEC 2018-02
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 61
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age > 18 years with no upper limit, Performance Status ECOG 0-2, Squamous cell carcinoma, previously untreated, T1-T4 with clinical status N0-N1, N2a or N2b non palpable, with only homolateral lymph node in radiological examinations., Patient with at least one of these fragility criteria : o Status ECOG 1 with multiple comorbidities, at least 2 pathologies with grade = 2 (renal and/or cardiac and/or vascular and/or hepatic, and/or neurologic, and/or pulmonary) o Status ECOG = 2 o Age = 70 , judged unfit with oncogeriatric evaluation by EGE (ELAN Geriatric Evaluation) test or unable to receive cisplatine or Carboplatine- 5FU (at least one criteria listed below*) * Criteria for determining if a patient is unfit for receiving cisplatine or carbo-5FU : Calculated creatinine clearance = 60 mL/min as determined by the modified. method of Cockcroft and Gault or glomerular filtration rate = 60 mL/min/1.73m² (CKD-EPI method recommended) Haemoglobin < 10 g/dL, aspartate (AST) and alanine transaminase (ALT) more than 2 times the upper limit of the normal range (ULN), serum albumin =35 g/L, Absolute neutrophil count = 1 500/µL, platelets = 100 000/µL or total bilirubin = 1.5 mg/dL Cardiac function not compatible with hyperhydration or significant heart disease Weight loss > 15% in 2 months, Oral cavity, oropharynx, hypopharynx or larynx, Documentation of p16 disease (HPV status for oropharyngeal tumor), Glomerular filtration rate (GFR) >40 mL/min/1.73m2 (CKD-EPI method recommended) or Calculated creatinine clearance CL>40 mL/min by the Cockcroft- Gault formula
排除标准
- •Nasopharyngeal, paranasal sinuses, nasal cavity tumors or thyroid cancers, Metastatic disease, Any prior or current treatment for invasive head and neck cancer, Any unresolved toxicity NCI CTCAE v5.0 Grade =2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. a. Patients with Grade =2 neuropathy will be evaluated on a case-by-case basis b. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the investigator, Body weight = 30 kg and/or weight loss of = 15% during the last 4 weeks (except if renutrition with a feeding tube is planned before the onset of treatment or is ongoing), Other severe acute or chronic medical conditions including pneumonitis, pulmonary fibrosis, Active autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]), Uncontrolled intercurrent illness, including but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
研究者
相似试验
进行中（未招募）
1 期
Trial evaluating the tolerance and safety of durvalumab - radiotherapy combination for treatment of cancers of the head and neckntreated Squamous cell carcinoma : Oral cavity, oropharynx, hypopharynx or larynxMedDRA version: 20.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001976-39-FRGORTEC73
已完成
2 期
Phase II trial of nivolumab following radiation therapy to bone metastases in patients with non-small cell lung cancernon-small cell lung cancer with bone metastasisJPRN-UMIN000025878niversity of Tsukuba Hospital30
进行中（未招募）
不适用
Phase II study of definitive radiochemotherapy for locally advanced squamous cell cancer of the vulva: an efficacy study - radiotherapy for vulvar canceradvanced stage squamous cell cancer of the vulvaMedDRA version: 8.1Level: LLTClassification code 10047777Term: Vulvar cancerEUCTR2006-004052-20-NLKoningin Wilhelmina Fonds
已完成
2 期
Phase II study of definitive radiochemotherapy for locally advanced squamous cell cancer of the vulva: an efficacy studyvulvar neoplasm1003859710029903vulvar cancerNL-OMON30199Academisch Medisch Centrum68
已完成
2 期
A phase II trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma (KDOG 0501 P2)locally advanced esophageal carcinomaJPRN-UMIN000002029Kitasato University School of Medicine35